Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepat… Read more
Assembly Biosciences Inc (ASMB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.083x
Based on the latest financial reports, Assembly Biosciences Inc (ASMB) has a cash flow conversion efficiency ratio of -0.083x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.13 Million) by net assets ($182.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Assembly Biosciences Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Assembly Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Assembly Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Assembly Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wholetech System Hitech Ltd
TWO:3402
|
0.201x |
|
Alto Ingredients Inc
NASDAQ:ALTO
|
0.102x |
|
Euglena Co. Ltd
F:8EG
|
0.017x |
|
Guangxi Fenglin Wood Industry Group Co Ltd
SHG:601996
|
0.039x |
|
Shenzhen Topway Video Communication Co Ltd
SHE:002238
|
0.017x |
|
Intelbras S.A. - Indústria de Telecomunicação Eletrônica Brasileira
SA:INTB3
|
0.150x |
|
Lagardere SA
PINK:LGDDF
|
0.497x |
|
ioneer Ltd
PINK:GSCCF
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Assembly Biosciences Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Assembly Biosciences Inc from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $33.36 Million | $-51.12 Million | -1.532x | -376.89% |
| 2023-12-31 | $41.10 Million | $22.74 Million | 0.553x | +154.16% |
| 2022-12-31 | $82.66 Million | $-84.46 Million | -1.022x | -84.81% |
| 2021-12-31 | $168.93 Million | $-93.40 Million | -0.553x | -111.27% |
| 2020-12-31 | $240.58 Million | $-62.96 Million | -0.262x | +14.95% |
| 2019-12-31 | $273.22 Million | $-84.07 Million | -0.308x | +0.22% |
| 2018-12-31 | $210.65 Million | $-64.96 Million | -0.308x | -1975.30% |
| 2017-12-31 | $113.12 Million | $1.86 Million | 0.016x | +103.77% |
| 2016-12-31 | $79.88 Million | $-34.88 Million | -0.437x | -177.33% |
| 2015-12-31 | $118.74 Million | $-18.70 Million | -0.157x | +38.41% |
| 2014-12-31 | $58.57 Million | $-14.97 Million | -0.256x | +64.81% |
| 2013-12-31 | $24.49 Million | $-17.80 Million | -0.727x | +39.48% |
| 2012-12-31 | $17.81 Million | $-21.38 Million | -1.200x | -65.36% |
| 2011-12-31 | $34.53 Million | $-25.07 Million | -0.726x | -61.86% |
| 2010-12-31 | $11.63 Million | $-5.21 Million | -0.449x | -272.03% |
| 2009-12-31 | $-13.36 Million | $-3.48 Million | 0.261x | -40.55% |
| 2008-12-31 | $-9.46 Million | $-4.15 Million | 0.439x | -- |